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Introduction
In recent years, much effort has been made to im-
prove the basic knowledge of radiation effects on nor-
mal and neoplastic cells, looking for an integration of
classical radiation biology with new emerging concepts
from the fields of genetics and molecular biology. The
advance has been substantial, with definition and clear
description of several signaling pathways involved in
cellular radiation response, but genetic determinants
and molecular mechanisms of clinical therapeutic ra-
diosensitivity are still poorly understood. Interindivid-
ual differences in the occurrence and severity of radia-
tion effects are a very common event in radiation oncol-
ogy. Furthermore, in the same patient a different grade
of toxicity in different tissues may be observed. Despite
the fact that multiple factors (age, nutritional status, co-
existing morbidities, fractionation schedule, treatment
volume, etc.) are responsible for this phenomenon,
probably a more profound biological difference exists
and contributes to interindividual variability of tumors
and normal tissue radiation-induced reactions. Available
data supporting the hypothesis that radiosensitivity is in
fact influenced by genetic factors and preliminary re-
sults of genetic assays currently under investigation are
presented and discussed, with the aim of delineating the
potential future implications in the field of radiation on-
cology.
Genetic syndromes and in vitro assays
Strong evidence in favor of a genetic basis of radia-
tion response originates from studies on patients with
rare genetic syndromes such as ataxia telangiectasia,
Fanconi’s anemia, Nijmegen Breakage syndrome and
Bloom’s syndrome. A small number of case reports of
patients affected by these diseases showed patterns of
enhanced cellular and clinical radiosensitivity and in-
creased susceptibility to cancer development1,2. These
syndromes are clearly related to germ line mutations re-
garding genes involved in detection of DNA damage or
DNA repair3. Mutations in repair genes have also been
detected in patients with reported extreme radiosensitiv-
ity, even if not affected by any of these syndromes2,4,5.
All of the cited genetic syndromes are very rare, charac-
terized by Mendelian inheritance and probably of limit-
ed importance when addressing the issue of clinical ra-
diosensitivity in a population of unselected cancer pa-
tients. However, as pointed out by different Authors6,7,
they could be considered as a “proof of principle” that
clinical radiosensitivity is in fact determined by genetic
factors.
The possible association between in vitro cell ra-
diosensitivity and clinical patterns of sensitivity among
unselected cancer patients is an experimental approach
that can be considered: few data are available, but the
correlation seems to be supported by a genetic basis.
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New insights into molecular mechanisms responsible for cel-
lular radiation response are coming from recent basic radio-
biological studies. Preliminary data supporting the concept
of clinical radiosensitivity as a complex genetically con-
trolled event are available, and it seems reasonable to hy-
pothesize that genes encoding for proteins implicated in
known radiation-induced pathways, such as DNA repair,
could influence normal tissue and tumor response to radio-
therapy. Such genes could be considered as candidates for
experimental studies and as targets for innovative therapies.
Variants that could influence individual radiosensitivity have
been recently identified, and specific Single Nucleotide Poly-
morphisms have been associated to the development of dif-
ferent radiation effects on normal tissues. Allelic architecture
of complex traits able to modify phenotypes is difficult to be
established, and different grades of interaction between com-
mon or rare genetic determinants may be present and should
be considered. Many different experimental strategies could
be investigated in the future, such as analysis of multiple
genes in large irradiated patient cohorts strictly observed for
radiation effects or identification of new candidate genes,
with the aim of identifying factors that could be employed in
predictive testing and individualization of radiation therapy
on a genetic basis.
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Some studies on “overeactors” have indicated that on
the average these patients exhibit a higher in vitro ra-
diosensitivity8,9. It has also been demonstrated that first-
degree relatives of breast cancer patients with increased
clinical radiosensitivity show increased in vitro ra-
diosensitivity compared to controls10,11.
Studies investigating the correlation between in vitro ra-
diosensitivity (with a variety of biological end points) and
clinical radiosensitivity in breast cancer patients have lead
to contradictory results or have not been found to predict
radiation toxic effects on normal tissues12-15. Twardella and
Chang-Claude13 reviewed 25 studies published between
1990 and 2000, with the aim of identifying which tests
should be considered most promising. In vitro assays were
classified in 4 groups: testing the ability to survive after
exposure to radiation, cytogenetic tests evaluating the fre-
quency of specific chromosomal aberrations in irradiated
cells, a cell’s ability to repair radiation-induced damages,
other radiation-induced end points like apoptosis13. Most
of these studies employed a study design that included pa-
tients previously submitted to radiation therapy and for
whom the severity of side effects was already known. The
biological end point of all the assays was an estimation of
cellular effects in terms of “cell lethality” and a correla-
tion with radiation-induced toxicity. An observation could
be made about the fact that acute and late effects on nor-
mal tissues are now better understood and clearly different
in their pathogenesis. For acute effects, the role of cellular
response evaluated by in vitro tests appears more clear
(even with contrasting experimental findings), whereas
late effects are probably not entirely dependent on cell
lethality and modulated by multiple factors (extracellular
matrix response, inflammatory cytokines, vascular dam-
age), making it more difficult to define a correlation with
cellular response of irradiated cells. 
Problems may also arise when evaluating late effects
in terms of the choice of the “control” group, taking into
account bias as prolonged survival (this is especially im-
portant in evaluating data of patients treated with aggres-
sive regimens for tumors with a poor prognosis). Due to
these considerations, Ferret and Hall6 observed that the
possibility to identify an in vitro assay showing suffi-
cient sensitivity and specificity in detecting individuals
who will probably develop acute or late clinical radia-
tion toxicity is highly debatable6. Anyway, getting closer
to the point of a genetic basis of clinical radiosensitivity,
a consideration could be made about the fact that the
weak correlation sometimes demonstrated between in
vitro data and clinical data seems likely to depend on ge-
netic factors. This hypothesis is supported by the current
knowledge on biological events (DNA repair or apopto-
sis) that can be now clearly regarded as genetically con-
trolled complex cellular phenomena.
Irradiated patient’s genotypes 
and clinical radiosensitivity
Since the ATM (Ataxia Telangiectasia Mutated) pro-
tein plays a central role in the detection of DNA dam-
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age and in activating DNA repair pathways, many stud-
ies have addressed the hypothesis that heterozygosis for
ATM mutation could be investigated in patients show-
ing higher clinical radiosensitivity. In vitro cells with
ATM heterozygosis show an intermediate radiosensitiv-
ity compared with cells from ataxia telangiectasia pa-
tients and healthy controls3. The frequency of heterozy-
gosis in general population is estimated to be approxi-
mately 0.5-1%, with probably a higher frequency (3-
5%) in a breast cancer patients’ population, since ATM
mutation carriers are at a 4-fold increased risk of breast
cancer16. Many of these studies, retrospectively review-
ing patients with severe reactions and looking for an un-
expected frequency of mutations, did not demonstrate
any correlation between ATM status and clinically en-
hanced radiosensitivity17-22. In a cohort of 13 patients
known to be heterozygotes, no adverse reactions were
recorded17. Iannuzzi et al.23 reported 2 missense or syn-
onymous ATM mutations in 3/3 breast cancer patients
showing grade 3-4 subcutaneous late reactions after ra-
diotherapy, whereas only 3 of 43 patients who did not
develop this form of severe toxicity were carriers of
ATM mutations. Interestingly, the authors did not em-
ploy the classical protein truncation test but a technique
capable of detecting single base substitutions (denatur-
ing high-performance liquid chromatography). Such al-
terations, especially if both alleles are affected, could be
of greater importance for clinical radiosensitivity in
terms of late reactions. No statistically significant corre-
lation was found with early effects, and the finding is
not clear if we think that ATM is the key sensor of DNA
damage by ionizing radiation (especially double-strand
breaks) and primarily involved in activating DNA repair
pathways in all tissues. 
Polymorphisms of the ATM gene were also investi-
gated in a cohort of 254 breast cancer patients, 70 of
them showing enhanced radiosensitivity24. A positive
association was found between some variant alleles,
with a complex finding regarding allelic architecture
(homozygote/heterozygote state) and a difficult expla-
nation from a mechanistic point of view, as pointed out
by Authors.
Alterations in the breast cancer susceptibility gene
BRCA1 also appear to be associated with radiosensitiv-
ity, based on results obtained from cell culture experi-
ments using BRCA1 protein-deficient cells25. BRCA
proteins are phosphorylated by ATM in response to
DNA damage and form complexes with RAD51. On
this basis, these proteins are believed to participate in
DNA damage sensing and repair pathways. In addition,
BRCA1 knocked-out mice are radiosensitives26. Carri-
ers of BRCA1 or BRCA2 mutations may have en-
hanced clinical radiosensitivity. The frequency of these
mutations in the general population is unknown27. In the
only reported clinical investigation correlating BRCA
status and enhanced clinical radiosensitivity, no muta-
tions were found in 22 patients with severe normal tis-
sue reactions (mutation detected with the protein trun-
cation test)28.
Gene mutations in DNA ligase IV4, a protein in-
volved in DNA repair, and Fanconi’s anemia29 gene
have been reported in radiosensitive cancer patients, as
anecdotal reports from a very small group of individu-
als investigated for these mutations.
Polymorphisms in XRCC1 and XRCC3, genes of
DNA repair pathway, were strongly associated with
clinical radiosensitivity in a paper by Price et al.30 in
1997. However, it was a small study, including 34
healthy controls and 19 cancer patients, 8 classified as
radiosensitives. XRCC1 knocked-out mice are extreme-
ly radiosensitive and XRCC1 is associated with genom-
ic instability, including increased frequency of sponta-
neous or induced chromosome translocations or dele-
tions31. The protein is implicated in every step of base
excision repair. Moullan et al.32 found a positive corre-
lation between XRCC1 polymorphisms and adverse re-
sponse to radiation therapy in a series of 70 radiosensi-
tive breast cancer patients. The impact of these poly-
morphisms on phenotypes is unclear, particularly when
multiple variants are present in a combined genotype.
Wang et al.33 correlated XRCC1 genotypes and level of
in vitro chromosomal damage (obtained with ra-
diomimetic drugs), finding a relation in individuals with
a specific polymorphism. Andreassen et al.34 established
a significant correlation between 5 single nucleotide
polymorphisms (SNPs) in 4 candidate genes, including
XRCC1 and XRCC3, and risk of radiation-induced nor-
mal tissue late reactions in breast cancer patients. Inter-
estingly, from these preliminary data it appears that the
presence of multiple significant polymorphic variants of
different genes in individual genotypes probably is able
to influence clinical radiosensitivity in a complex way.
Quarnby et al.35 found that certain SNPs in the
TGFβ1 gene were associated with radiation-induced fi-
brosis. This multifunctional cytokine is involved in pro-
moting tissue fibrosis, and pre-treatment plasma TGFβ1
levels are linked to the risk of developing subcutaneous
fibrosis36. Homozygotes for these variants are 7-15
times more likely to develop severe fibrosis35. Polymor-
phisms of TGFβ1 were associated with increased risk of
subcutaneous fibrosis in breast cancer patients also in
Andreassen’s paper34.
Variants in the hHR21 gene have also been detected
in radiosensitive cancer patients36. Six of 19 radiosensi-
tive patients showed a variant in DNA sequence, not
modifying the encoded amino acid. No information is
available about the frequency in the general population. 
The superoxide dismutase protein encoded by gene
SOD2 is one of the major players in the defense against
oxidative damage by radiation-induced free radicals.
Polymorphisms in this candidate gene have been inves-
tigated and are believed to impact on protein function.
Data from the study by Green et al.37 showed a negative
correlation between the investigated variant (Ala9Val)
and radiotherapy reactions. The SOD2 codon 16
Val/Ala genotype was associated with the risk of subcu-
taneous fibrosis compared to the Val/Val genotype34.
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Genetic manipulation of radiosensitivity
Begg and Vens38 recently reviewed a number of stud-
ies on genetic manipulation of radiosensitivity, consid-
ering different strategies. Two main approaches were
described: to introduce or express antisense oligonu-
cleotides which hybridize with mRNA and prevent
translation; to overexpress a protein or a peptide (lack-
ing an essential activity, called dominant negative) that
competes with wildtype protein. 
Poly ADO-ribose polymerase recognizes and binds to
DNA strand breaks, activating the polymerase which
then modifies chromatin structure39,40. Rudat et al.41
demonstrated that expression of only the DNA binding
domain leads to radiosensitization. 
The G1/S checkpoint after ionizing radiation is p53
dependent, and abrogation of p53 function by overex-
pressing mutant p53 leads to increased resistance to ra-
diation42.
Signals from stimulatory or inhibitory pathways ulti-
mately lead to transcription of genes. The cAMP re-
sponse element (CRE) binding protein, CREB, is in-
volved in initiating transcription from genes containing
the CRE sequence in their promoters. Expression of
dominant negative CREB proteins with lack of DNA
binding activity can lead to radiosensitization43. Modifi-
cation of other transcription factors can lead to changes
in cell radiosensitivity: clones containing inducible
dominant negative constructs to C-JUN and EGFR1 had
reduced survival to irradiation44.
Expression of ATM can be reduced using antisense con-
structs with concomitant increases in radiosensitivity45,46.
Mammalian cells with homozygously deleted RAD54
(RAD52 genes family, involved in homologous recom-
bination) showed markedly increased radiosensitivity47,
and antisense oligonucleotides to RAD51 have been
shown to radiosensitize mouse glioma cells48. 
These studies provide a large number of possible tar-
gets potentially relevant to therapy, but are also another
indirect evidence of the genetic basis of cellular radia-
tion response.
Discussion
In a complete review on genetic basis of interindivid-
ual differences in normal tissues radiosensitivity, An-
dreassen et al.7 defined and discussed the hypothesis
that clinical radiosensitivity could be considered a ge-
netic complex trait. This concept is based on the pre-
sented data on the genetic basis of radiation response,
showing some evidence but also some unclear findings.
The risk of so-called complex diseases depends on in-
teractions between environmental factors and suscepti-
bility alleles in a large number of genes49. It seems rea-
sonable to suppose that clinical response to a course of
radiotherapy should be regarded as a complex pheno-
type depending on the combined effects of several ge-
netic alterations7. In this scenario, SNPs, previously re-
garded as genetic variations without functional signifi-
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cance, now represent a very interesting field of research
in radiation biology, showing early promising results as
mentioned below. SNPs are potentially able to affect
phenotype and could be located in regulatory regions,
influencing gene expression, or in coding regions, caus-
ing amino acid changes that may alter protein function.
SNPs in non-coding regions may affect DNA splicing
or stability.
The allelic architecture of complex traits is clearly
difficult to define in details, and different competing
models could be considered. Probably, the basis is made
up of common and rare genetic variants, and evidence
is consistent with a model of genetic influence in which
a large number of variants impact on radiosensitivity at
different levels, generally or exclusively in certain types
of tissues or through certain types of reactions7. More-
over, if clinical radiosensitivity is a phenomenon mainly
dependent on a number of rare genetic variants in a
large pool of potential loci, a high degree of heterogene-
ity is expected, with the same phenotype that could be
determined by different genotypes. The candidate gene
approach is based on the concept that genes known to
be involved in radiation-induced phenotypes, like DNA
repair genes (such as XRCC1, ATM) or pro-inflamma-
tory cytokines genes (TGFβ1), should be the first to be
investigated when designing experimental studies on
the correlation between genetic variants and clinical ra-
diosensitivity. This is a good way to study possible cor-
relations with clinical radiosensitivity, but probably un-
able to explain some complex radiation-induced biolog-
ical events that we still not know in details. The recent
introduction of DNA microarray technology, with origi-
nal data coming from early papers showing a correla-
tion between specific gene expression profiles and ra-
diosensitivity or the induction of expression of previ-
ously unexpected genes after in vitro irradiation50-52 may
help us to identify new candidate genes and to explain,
from a genetic point of view, extremely different radia-
tion effects in cancer patients. Preliminary findings on
the correlation between radiation-induced toxicity and
abnormal transcription responses to DNA damage are
encouraging. A study by Rieger et al.53 showed that
transcriptional responses in 24 genes were able to pre-
dict radiation toxicity in 64% of 14 radiosensitive pa-
tients included in the study. Twenty of the 24 genes con-
tributed to ionizing radiation response (DNA repair
processes, stress response, ubiquitin/proteasome path-
ways, apoptosis, cell cycle control). A critical point in
this approach, as pointed out by the Authors, is that it is
not able to identify the genetic basis for toxicity, be-
cause predictive genes may not be mutated and may re-
spond abnormally due to mutation in other genes, or as
a result of a combined effect of polymorphisms in sev-
eral genes. Complex interactions between genetic vari-
ants may be present and should be considered, such as
the fact that environmental and epigenetic factors may
influence radiosensitivity. Several ongoing trials are
based on the genetic study of small groups of overreac-
tors or large groups of consecutive patients carefully
monitored for acute and late reactions (probably a more
correct approach)7. The concept of clinical radiosensi-
tivity as a genetically controlled complex event still re-
mains to be fully understood, and many issues have to
be dealt with, primarily the best experimental strategy.
Anyway, analyzing available data, we could say that in
the field of applied radiobiology the role of genetic
studies is probably the key to better understand radia-
tion effects on human tissues.
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